Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model

Cancer Letters

Volumn 214, Issue 2, 2004, Pages 171-179

  Sigounas, George ^a   Sallah, Sabah ^b   Sigounas, Vaia Y ^a  

^a Carolina University in Greenville   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Chemotherapy; Erythropoietin; Lung cancer; Modulators

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; MITOMYCIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; INOCULATION; LEWIS CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ERYTHROPOIETIN; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MITOMYCIN; NEOPLASM METASTASIS;

ANIMALIA; MURINAE;

EID: 4444318802     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.06.009     Document Type: Article

References (42)

1. W. Dalton Drug resistance modulation in the laboratory and the clinic Semin. Oncol. 20 1993 64 69
2. I.J. Fidler Critical determinants of cancer metastasis: rationale for therapy Cancer Chemother. Pharmacol. 43 Suppl 1999 S3 S10
3. R.S. Bush, R.D.T. Jenkin, W.E.C. Allt, F.A. Beale, H. Bean, and A.J. Dembo Definitive evidence for hypoxic cells influencing cure in cancer therapy Br. J. Cancer 37 Suppl. 3 1978 302 306
4. T.G. Graeber, C. Osmanian, T. Jacks, D.E. Housman, C.K. Koch, and S.W. Lowe Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours Nature 379 1996 88 91
5. J.M. Brown, and A.J. Giaccia The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res. 58 1998 1408 1416
6. J.M. Brown Sensitizers and protectors in radiotherapy Cancer 55 1985 2222 2228
7. C. Grau, and J. Overgaard Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay Radiother. Oncol. 13 1988 301 309
8. O. Thews, R. Koenig, D.K. Kelleher, J. Kutzner, and P. Vaupel Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia Br. J. Cancer 78 1998 752 756
9. C.M. Glaser, W. Millesi, G.V. Kornek, S. Lang, B. Schüll, and F. Watzinger Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int. J. Radiat. Oncol. Biol. Phys. 50 2001 705 715
10. D.F. Silver, and M.S. Piver Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect Gynecol. Oncol. 73 1999 280 284
11. J. Glapsy, R. Bukowski, D. Steinberg, C. Taylor, S. Tchekmedyian, and S. Vadhan-Raj Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice J. Clin. Oncol. 15 1997 1218 1234
12. G.D. Demetri, M. Kris, J. Wade, L. Degos, and D. Cella Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study J. Clin. Oncol. 16 1998 3412 3425
13. T.J. Littlewood The impact of hemoglobin levels on treatment outcomes in patients with cancer Semin. Oncol. 28 2 Suppl. 8 2001 49 53
14. T.J. Littlewood, E. Bajetta, J.W.R. Nortier, E. Vercammen, and B. Rapoport Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J. Clin. Oncol. 19 2001 2865 2874
15. J.L. Gabrilove, C.S. Cleeland, R.B. Livingston, B. Sarokhan, E. Winer, and L.H. Einhorn Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J. Clin. Oncol. 19 2001 2875 2882
16. L. Fallowfield, D. Gagnon, M. Zagari, D. Cella, B. Bresnahan, and T.J. Littlewood Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study to confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy Br. J. Cancer 87 2002 1341 1353
17. T.R. Lappin, A.P. Maxwell, and P.G. Johnston EPO's alter ego: erythropoietin has multiple actions Stem Cells 20 2002 485 492
18. Z.Z. Chong, J. Kang, and K. Maiese Angiogenesis and plasticity: role of erythropoietin in vascular systems J. Hematoth. Stem Cell Res. 11 2002 863 871
19. G. Sigounas, K. Salleng, P. Mehlhop, S. Sallah, M. Collins, and A. Kardatos Erythropoietin inhibits drug-induced fibrosis and improves pulmonary function Blood 98 11 2001 798a
20. J.S. Bertram, and P. Janik Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture Cancer Lett. 11 1980 63 73
21. H. Wexler Accurate identification of experimental pulmonary metastases J. Nat. Cancer Inst. 36 1966 641 645
22. P.H. Maxwell, G.U. Dachs, J.M. Gleadle, L.G. Nicholls, A.L. Harris, and I.J. Stratford Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc. Natl Acad. Sci. (USA) 94 1997 8104 8109
23. E.K. Rofstad, and T. Danielsen Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis Br. J. Cancer 80 1999 1697 1707
24. E.K. Rofstad Microenvironment-induced cancer metastasis Int. J. Radiat. Biol. 76 2000 589 605
25. G.L. Semenza Hypoxia, clonal selection, and the role of HIF-1 in tumor progression Crit. Rev. Biochem. Mol. Biol. 35 2 2000 71 103
26. J. Fang, L. Yan, Y. Shing, and M.A. Moses HIF-1α-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis Cancer Res. 61 2001 5731 5735
27. D. Shasha The negative impact of anemia on radiotherapy and chemoradiation outcomes Semin. Hematol. 38 Suppl. 7 2001 8 15
28. M. Henke, R. Laszig, C. Rube, U. Schafer, K. Haase, and B. Schilcher Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial, Lancet 362 9392 2003 1255 1260
29. F.R. Luo, S.D. Wyrick, and S.G. Chaney Biotransformations of oxaliplatin in rat blood in vitro J. Biochem. Mol. Toxicol. 13 3-4 1999 159 169
30. L. Balducci, and L. Carreca The role of myelopoietic growth factors in managing cancer in the elderly Drugs 62 Suppl. 1 2002 47 63
31. M. Mittelman, D. Neumann, A. Peled, P. Kanter, and N. Haran-Ghera Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models Proc. Natl Acad. Sci. USA 98 2001 5181 5186
32. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
33. B.R. Zetter Angiogenesis and tumor metastasis Annu. Rev. Med. 49 1998 407 424
34. M. Steiner, T. Madigan, A. Anagnostou, and G. Sigounas Cloning and characterization of erythropoietin receptor forms of human vascular endothelial cells Blood 90 Suppl. 1 1997 290a
35. Y. Yasuda, S. Masuda, M. Chikuma, K. Inoue, M. Nagao, and R. Sasaki Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis J. Biol. Chem. 273 1998 25381 25387
36. D. Ribatti, M. Presta, A. Vacca, R. Ria, R. Giuliani, and P. Dell'Era Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo Blood 93 1999 2627 2636
37. S.A. Cannistra, P. Groshek, and J.D. Griffin Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia Leukemia 3 5 1989 328 334
38. G. Acs, P. Acs, S.M. Beckwith, R.L. Pitts, E. Clements, and K. Wong Erythropoietin and erythropoietin receptor expression in human cancer Cancer Res. 61 2001 3561 3565
39. T. Browder, C.E. Butterfield, B.M. Kräling, B. Shi, B. Marshall, and M.S. O'Reilly Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res. 60 7 2000 1878 1886
40. V.J. Spanswick, J. Cummings, and J.F. Smyth Enzymology of mitomycin C metabolic activation in tumour tissue Biochem. Pharmacol. 51 1996 1623 1630
41. 5 reductase activity increases the cytotoxicity of mitomycin C (MC) and the total number of MC-DNA adducts in chinese hamster ovary cells J. Biol. Chem. 278 2003 5029 5034
42. T.S. Herman, B.A. Teicher, and L.S. Collins Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures Cancer Res. 48 1988 2342 2347